Karyopharm Therapeutics(KPTI) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenu ...